Company Overview
1910 Genetics is the only company that has built a synergistic, dual-purpose small and large molecule platform that integrates artificial intelligence (AI), computation, and biological automation to design drug-like molecules better, faster, and cheaper than traditional approaches.
Based in the Seaport District of Boston, 1910 Genetics is a Series A stage biotechnology startup that was founded in 2018 and is backed by prestigious investors, including M12-Microsoft's Venture Fund, Sam Altman - the CEO of OpenAI (makers of ChatGPT), Playground Global, Y Combinator, New Ventures Funds (Scientia Ventures), and many others.
At 1910 Genetics, we first establish an understanding of the molecular basis of disease to the granularity at which the world understands sickle cell anemia. This understanding centers biology as our North Star and drives our integration of artificial intelligence (AI), computation, and biological automation to accelerate the design of small molecule and protein therapeutics.
Recent advances in computational technologies have placed historically "undruggable" targets within therapeutic reach. But at 1910 Genetics, we often say "Biology is King," meaning that computational technologies are only impactful in drug discovery when driven by experimental biology. Our platforms' scale and breadth empower us to be therapeutic area-agnostic with programs ranging from neuroscience and immunology to infectious disease and oncology, to name a few.
You are someone we can count on to...
Collaborate closely with cross-functional teams, including data scientists, AI/ML Engineers, Bioinformaticians, and domain experts, to build scalable data pipelines, integrate machine learning models, and ensure seamless platform functionality.
Play a pivotal role in designing, developing, and maintaining a state-of-the-art cloud-based platform that empowers our scientists and researchers to make groundbreaking advancements in drug discovery.